These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8686186)

  • 41. Anti-inflammatory peptides and proteins in inflammatory bowel disease.
    Veljaca M
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1387-94. PubMed ID: 11890353
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Free radicals in inflammatory bowel diseases pathophysiology and therapeutic implications.
    Gross V; Arndt H; Andus T; Palitzsch KD; Schölmerich J
    Hepatogastroenterology; 1994 Aug; 41(4):320-7. PubMed ID: 7959565
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 5-aminosalicylates in inflammatory bowel disease and chronic renal failure.
    Tekin F; Ozutemiz O; Ilter T
    Aliment Pharmacol Ther; 2005 Sep; 22(6):579; author reply 579-80. PubMed ID: 16167976
    [No Abstract]   [Full Text] [Related]  

  • 44. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
    [No Abstract]   [Full Text] [Related]  

  • 45. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
    Mulder CJ; van den Hazel SJ
    Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of inflammatory bowel disease during pregnancy and nursing.
    Friedman S
    Semin Gastrointest Dis; 2001 Oct; 12(4):245-52. PubMed ID: 11726078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Terminal ileitis in childhood: Crohn disease or gastrointestinal tuberculosis?].
    Kroon AA; Ramaker C; Keessen M; Derkx HH; Büller HA; Taminiau JA
    Ned Tijdschr Geneeskd; 1995 Oct; 139(40):2017-20. PubMed ID: 7477547
    [No Abstract]   [Full Text] [Related]  

  • 48. Optimizing therapy for inflammatory bowel disease.
    Robinson M
    Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
    Shah JA; Edwards CM; Probert CS
    Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):169-73. PubMed ID: 18301295
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [New derivates of salazopyrine in the treatment of chronic inflammatory bowel disease].
    Broide E; Scapa E; Abramowich D; Eshchar Y
    Harefuah; 1993 Feb; 124(4):223-5. PubMed ID: 8098698
    [No Abstract]   [Full Text] [Related]  

  • 51. 5-Aminosalicylates in inflammatory bowel disease: choosing the right dose.
    Qasim A; Seery J; O'Morain CA
    Dig Liver Dis; 2001; 33(5):393-8. PubMed ID: 11529648
    [No Abstract]   [Full Text] [Related]  

  • 52. Current drug therapy for inflammatory bowel disease.
    Ogorek CP; Fisher RS
    Compr Ther; 1991 Apr; 17(4):31-7. PubMed ID: 1879116
    [No Abstract]   [Full Text] [Related]  

  • 53. Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome.
    Tebano MT; Traversa G; Da Cas R; Loizzo A
    Aliment Pharmacol Ther; 1996 Aug; 10(4):659-63. PubMed ID: 8853773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Aminosalicylates and chronic inflammatory diseases of the digestive tract].
    Loizeau E
    Rev Med Suisse Romande; 1987 Jul; 107(7):549-51. PubMed ID: 3629067
    [No Abstract]   [Full Text] [Related]  

  • 55. [5-aminosalicylic acid-associated pancreatitis].
    Tromm A; May B
    Dtsch Med Wochenschr; 1991 Jul; 116(28-29):1125. PubMed ID: 2065601
    [No Abstract]   [Full Text] [Related]  

  • 56. [Pharmaclinics--how I treat... Crohn disease].
    Belaiche J
    Rev Med Liege; 1995 Oct; 50(10):409-10. PubMed ID: 7491437
    [No Abstract]   [Full Text] [Related]  

  • 57. Experience with Eudragit-S coated mesalamine (Asacol) in inflammatory bowel disease: adverse events.
    Nichols TW
    J Clin Gastroenterol; 1994 Mar; 18(2):181. PubMed ID: 8189029
    [No Abstract]   [Full Text] [Related]  

  • 58. Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease.
    Wallace JL
    Dig Liver Dis; 2003 May; 35 Suppl 2():S35-40. PubMed ID: 12846442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New approaches may aid patients with inflammatory bowel disease.
    Cotton P
    JAMA; 1990 Jun; 263(23):3121-2. PubMed ID: 2348514
    [No Abstract]   [Full Text] [Related]  

  • 60. Aminosalicylates for the treatment of inflammatory bowel disease.
    Leichtner AM
    J Pediatr Gastroenterol Nutr; 1995 Oct; 21(3):245-52. PubMed ID: 8523207
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.